CNS Pharmaceuticals's total assets for Q2 2025 were $14.51M, an increase of 5.52% from the previous quarter. CNSP total liabilities were $1.38M for the fiscal quarter, a -50.24% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.